Literature DB >> 10400695

The CD3-gamma delta epsilon transducing module mediates CD38-induced protein-tyrosine kinase and mitogen-activated protein kinase activation in Jurkat T cells.

M Zubiaur1, M Guirado, C Terhorst, F Malavasi, J Sancho.   

Abstract

We have examined the ability of the CD3-gamma delta epsilon and CD3-zeta signaling modules of the T cell receptor (TCR) to couple CD38 to intracellular signaling pathways. The results demonstrated that in TCR+ T cells that express the whole set of CD3 subunits CD38 ligation led to complete tyrosine phosphorylation of both CD3-zeta and CD3-epsilon polypeptide chains. In contrast, in TCR+ cells with a defective CD3-zeta association CD38 engagement caused tyrosine phosphorylation of CD3-epsilon but not of CD3-zeta. Despite these differences, in both cell types CD38 ligation resulted in protein-tyrosine kinase and mitogen-activated protein kinase activation. However, in cells expressing chimerical CD25-zeta or CD25-epsilon receptors or in a TCR-beta- Jurkat T cell line, CD38 ligation did not result in tyrosine phosphorylation of the chimeric receptors, or CD3 subunits, or protein-tyrosine kinase or mitogen-activated protein kinase activation. In summary, these results support a model in which CD38 transduces activating signals inside the cell by means of CD3-epsilon and CD3-zeta tyrosine phosphorylation. Moreover, these data identify the CD3-gamma delta epsilon signaling module as a necessary and sufficient component of the TCR/CD3 complex involved in T cell activation through CD38.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400695     DOI: 10.1074/jbc.274.29.20633

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity.

Authors:  Johanna Congleton; Miaoqing Shen; Robert MacDonald; Fabio Malavasi; Andrew Yen
Journal:  Cell Signal       Date:  2014-03-29       Impact factor: 4.315

Review 2.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

3.  ATRA-induced HL-60 myeloid leukemia cell differentiation depends on the CD38 cytosolic tail needed for membrane localization, but CD38 enzymatic activity is unnecessary.

Authors:  Johanna Congleton; Hong Jiang; Fabio Malavasi; Hening Lin; Andrew Yen
Journal:  Exp Cell Res       Date:  2010-12-13       Impact factor: 3.905

4.  Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.

Authors:  Angélique Biancotto; Jean-Charles Grivel; Sarah J Iglehart; Christophe Vanpouille; Andrea Lisco; Scott F Sieg; Robert Debernardo; Kristen Garate; Benigno Rodriguez; Leonid B Margolis; Michael M Lederman
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

5.  The CD19/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes.

Authors:  Felipe Vences-Catalán; Ranjani Rajapaksa; Shoshana Levy; Leopoldo Santos-Argumedo
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

Review 6.  CD38: T Cell Immuno-Metabolic Modulator.

Authors:  Anwesha Kar; Shikhar Mehrotra; Shilpak Chatterjee
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

7.  CD38 Correlates with an Immunosuppressive Treg Phenotype in Lupus-Prone Mice.

Authors:  Jocelyn C Pérez-Lara; Enrique Espinosa; Leopoldo Santos-Argumedo; Héctor Romero-Ramírez; Gabriela López-Herrera; Fabio García-García; Claudia Sandoval-Montes; Vianney Ortiz-Navarrete; Mónica Flores-Muñoz; Juan C Rodríguez-Alba
Journal:  Int J Mol Sci       Date:  2021-11-05       Impact factor: 5.923

Review 8.  Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.

Authors:  Fátima Bayón-Calderón; María L Toribio; Sara González-García
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.